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Virus C infection has been associated with a broad spectrum of
extrahepatic diseases such as essential mixed cryoglobulinemia, mem-
branous glomerulonephritis, vasculitis, rheumatoid arthritis and lupus
erythematosus. The etiologic role of virus C has also been observed in
some neoplasms such as non-Hodgkin’s lymphoma and the mono-
clonal gammapathies. Many studies also support the link between this
virus and porphyria cutanea tarda (PCT). Isolated cases suggest a
relationship with dermatomyositis. Herein, we report the coexistence
of PCT, non-Hodgkin’s lymphoma and dermatomyositis in the same
patient affected with virus C infection which has never previously been
described.
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Case report
A 57-year-old male patient, without known risk factors,
was affected with chronic hepatitis C virus (HCV) infec-
tion for five years under treatment with IFN-alpha 3 × 106
IU three times a week for two years. He also presented a
two-year history of non-Hodgkin’s lymphoplasmocytoid
lymphoma stage IV A (axillar and cervical lymphadeno-
pathies, liver and splenic infiltration), treated with CHOP
(cyclophosphamide, adriamicin, vincristine and pred-
nisone) chemotherapy with complete remission for one
year. He consulted with crops of blister-like lesions on the
back of the hands and arms (Fig. 1), and hypertrichosis in
both malar regions during the previous month. A concen-
tration of 8930 micrograms/24 hours uroporphyrins (0-
40 micrograms/24 h) was detected in urine with normal
coproporphyrin and porphobilinogen concentrations
which confirmed the suspected diagnosis of porphyria
cutanea tarda (PCT). Ferritin levels were 1270 ng/ml
(70-435 ng/ml). One month later the patient presented
with a cervical bultoma diagnosed as recurrence of his
lymphoma after lymph node biopsy. At the same time, the
patient presented asymptomatic maculo-erythematous le-
sions on the back of the interphalangeal, metacarpopha-
langeal and elbow joints (Gottron’s sign) (Fig. 2), a
poikilodermic plaque on the scalp (Fig. 3), palpebral
violaceous erythema and periungual telangiectasias that
had developed in the previous weeks. In addition, the
patient complained of intense muscular weakness in the
scapular and pelvic muscles and also dysphagia for
liquids. These clinical manifestations were associated with
abnormal muscular enzyme tests; slightly raised creatin
phosphokinase (CPK): 139 (0-130), liver function tests:
AST 52 (1-25) and ALT 66 (1-29), with normal LDH and
aldolase levels and the presence of antinuclear antibodies
(ANA) at a titer of 1/80 with negative extractable nuclear
Figure 2. Gottron’s sign on the back of the metacarpopha-
langeal joints.
Figure 1. Multiple crusts and millium cysts on the back of the
hands.
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antibodies (ENA). A skin biopsy from the hand lesions
showed epidermal necrosis with the presence of a subepi-
dermal bulla infiltrated by neutrophils, capillary trombosis
and an inflammatory infiltrate in the dermis composed of
neutrophils and eosinophils. Direct immunofluorescence
showed linear deposition of IgG, IgA, C3 and C1q along
the basal membrane and around vessels. All these findings
suggested the diagnosis of dermatomyositis. The patient
refused further diagnostic tests. After starting chemo-
therapy with CHOP, partial remission (50% reduction of
the cervical mass) of the lymphoma was achieved, with a
recovery of the muscular strength, disappearance of the
skin lesions and improvement of some analytic param-
eters: reduction of uroporphyrins (1767 micro-
grams/24 hours), normalization of CPK with persistence
of ANA (1/80) and raised AST and ALT.
Infection by HCV is a frequent cause of post-transfusion
hepatitis and the commonest cause of chronic viral hepa-
titis. Chronic HCV, leads to the appearance of cirrhosis
and hepatocellular carcinoma and may encourage the
development of a sustained immune response (Table I)
[1], by stimulating the lymphocytes, with the appearance
of a wide range of autoimmune diseases (Table II). The
association between virus C and certain extrahepatic
diseases has been strongly demonstrated, whereas in other
cases this relationship is weaker (Table II) [2].
The simultaneous presence in one patient with chronic
HCV of B cell lymphoma, PCT and dermatomyositis has
never been described before. In this case, HCV could be
considered the causal factor of all three pathologies, each
of which has individually been associated with this virus
in the literature. Regarding PCT, the association with
HCV is well known [3]. In southern Europe, 70-90% of
patients with porphyria have HCV. There are two hypoth-
eses about the way this virus may trigger porphyria: by the
increase in oxidative stress in the hepatocytes (the most
important mechanism), or by the development of auto-
antibodies which inhibit uroporphyrinogen decarboxylase
[2]. Other factors are probably implicated. Regarding
lymphoma, a prevalence of 20-40% of virus C antibodies
has been found in patients with low grade B lymphoma,
above all if these are associated with cryoglobulinemia or
if they are gastrointestinal MALT (mucosal associated
lymphoid tumors). This association can be explained by a
maintained proliferation of B cells by the virus, with the
development of monoclonality [2]. Perhaps the weakest
association of HCV is with dermatomyositis/polymyositis
which has not properly been demonstrated [4, 5].
None the less, the lymphoma might be the triggering
factor for porphyria and dermatomyositis in this case. This
hypothesis would be supported by the appearance of the
two diseases when the lymphoma recurred, and by the
clinical and analytical improvement when chemotherapy
was given, without receiving any other specific treatment
for these two diseases. Many studies associate dermato-
myositis with neoplasms [6], and some suggest a possible
relationship between PCT and certain extrahepatic tumors
[7], including lymphoma [8]. Some authors even recom-
mend a full clinical check for lymphomas in patients with
PCT [7].
Besides, the appearance of PCT together with autoim-
mune diseases has also been described, particularly with
Figure 3. Poikilodermic plaque located on the scalp.
Table I. Serologic findings associated with virus hepatitis C
infection
Antinuclear antibodies
Anticardiolipin antibodies
Antithyroid antibodies
Anti-smooth muscle antibodies
Anti-liver/kidney/microsomal antibodies
Rheumatoid factor
Table II. Extrahepatic diseases or manifestations associated
with virus hepatitis C infection
Autoimmune Non autoimmune
Mixed Cryoglobulinemia* Mucosal-associated lymphoid
tumors (MALT)
Autoimmune thyroiditis* Non-Hodgkin B-cell
lymphoma +
Membranoproliferative
glomerulonephritis +
Porphyria cutanea tarda
Lichen planus Plasmocytoma
Erythema multiforme + Pruritus
Autoimmune
thrombocytopenic purpura
Necrolytic acral erythema
Lymphocytic syaloadenitis
(Sjögren’s like) +
Urticaria +
Rheumatoid arthritis +
Mooren’s corneal ulcer
Leukocytoclastic vasculitis +
Antiphospholipid syndrome
Erythema nodosum +
Dermatomyositis/polymyositis
Vitiligo
Behçet’s syndrome
Polyarteritis nodosa
Systemic lupus erythematosus
Canities
Hyde’s prurigo nodularis
* Documented or highly probable association [14]
+ Frequently related to mixed cryoglobulinemia [14]
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systemic lupus erythematosus [9], but also with hemolytic
anemia, sclerodermia and in a single case with dermato-
myositis [10].
Lastly, IFN treatment, that was started two years before
the appearance of the PCT, might be responsible for the
development of PCT and dermatomyositis. Previous re-
ports have suggested these associations [11, 12] and some
authors recommend that patients treated with IFN should
be monitored for signs and symptoms of autoimmunity
[13]. For this reason the use of IFN-alpha in the treatment
of autoimmune diseases associated with HCV is contro-
versial [1]. Treatment with corticosteroids, azathioprine
and cyclophosphamid has proved effective, although the
viremia persists or may worsen [1].
In conclusion, we consider that the clinical manifestations
secondary to HCV infection are taking on increasing
importance for the dermatologist, and it is therefore vital
to gain a better understanding of this issue. In this case, we
show the simultaneous presence of dermatomyositis and
PCT associated with HCV infection, lymphoma and/or
IFN treatment. We believe that only the description of
similar cases will enable us to shed more light on the
etiologic role played by virus C infection, IFN and/or
lymphoma, together or singly, in the simultaneous occur-
rence of these diseases. j
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